-

Quince Therapeutics to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that management will present at three upcoming investor conferences:

  • 2024 Maxim Healthcare Virtual Summit – Quince’s Chief Executive Officer and Chief Medical Officer Dirk Thye, M.D., will participate in a fireside chat on Thursday, October 17, 2024 beginning at 3:00 p.m. Eastern Time. Qualified investors can register here to access the live event.
  • LD Micro Main Event XVII – Quince’s Chief Operating Officer and Chief Business Officer Brendan Hannah will present a company overview on Tuesday, October 29, 2024 beginning at 6:30 p.m. Eastern Time. Please register here to access the live presentation.
  • The ThinkEquity Conference 2024 – Quince’s President Charles Ryan, J.D., Ph.D., will present a company overview on October 30, 2024 beginning at 3:00 p.m. Eastern Time. A webcast of the presentation will be accessible here on the Events page of Quince’s Investor Relations website.

About Quince Therapeutics

Quince Therapeutics (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince Therapeutics on social media platforms LinkedIn, Facebook, X, and YouTube.

Contacts

Media & Investor Contact:
Stacy Roughan
Quince Therapeutics, Inc.
Vice President, Corporate Communications & Investor Relations
ir@quincetx.com

Quince Therapeutics, Inc.

NASDAQ:QNCX

Release Versions
$Cashtags

Contacts

Media & Investor Contact:
Stacy Roughan
Quince Therapeutics, Inc.
Vice President, Corporate Communications & Investor Relations
ir@quincetx.com

Social Media Profiles
More News From Quince Therapeutics, Inc.

Quince Therapeutics to Participate at Investor Events in December 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that senior management will participate at three investor events in December 2025: Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will participate at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025,...

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the third quarter ended September 30, 2025. Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, “Quince remains on track to report topline results for...

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the positive outcome of its pre-planned safety analysis conducted by an independent data and safety monitoring board (iDSMB) for the company’s ongoing pivotal Phase 3 NEAT (Neurological Effects of eDSP in Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical tria...
Back to Newsroom